SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-062611
Filing Date
2021-11-30
Accepted
2021-11-30 17:07:05
Documents
16
Period of Report
2021-11-22
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea151551-8k_rasnathera.htm   iXBRL 8-K 34724
2 LETTER FROM MARCUM LLP DATED NOVEMBER 30, 2021 ea151551ex16-1_rasnathera.htm EX-16.1 5866
6 GRAPHIC ex16-1_001.jpg GRAPHIC 5328
7 GRAPHIC ex16-1_002.jpg GRAPHIC 2713
8 GRAPHIC ex16-1_003.jpg GRAPHIC 1509
  Complete submission text file 0001213900-21-062611.txt   223178

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE rasp-20211122.xsd EX-101.SCH 3016
4 XBRL LABEL FILE rasp-20211122_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE rasp-20211122_pre.xml EX-101.PRE 22353
9 EXTRACTED XBRL INSTANCE DOCUMENT ea151551-8k_rasnathera_htm.xml XML 3286
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 333-191083 | Film No.: 211460320
SIC: 2834 Pharmaceutical Preparations